Amgen Said to Boost Bid for Onyx to $130 a Share

Aug. 6 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)

Google Search: Crystal Ball for Election Results?
45:55 - Khosla Ventures partner Keith Rabois, Braintree head of commerce Harper Reed and Bloomberg’s Tim Higgins discuss how campaigns can use Google search data with Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Apple Said to Produce New Show Starring Dr. Dre
  • Can PayPal Commerce Stand Up to Competition?
  • How Medium Recruits High Profile Writers